drugset / Trial / NCT06277154
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and efficacy of MASCT-I combined with Doxorubicin and Ifosfamide for first-line treatment in patients with advanced soft tissue sarcoma.
Timeline
- Start
- 2024-02-21
- Primary completion
- 2026-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MASCT-I | Cell therapy | — | Subcutaneous |
| Background | Doxorubicin | Other / unclassified | — | — |
| Background | Ifosfamide | Small molecule | — | — |